openPR Logo
Press release

Angina Pectoris Drugs Market Analysis 2024 -2033: Forecasted Market Size, Top Segments, And Largest Region | Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Amgen Inc., Gilead Sciences Inc., Bausch Health Companies Inc

Angina Pectoris Drugs  Market Characteristics

Angina Pectoris Drugs Market Characteristics

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2096

The Business Research Company offers in-depth market insights through Angina Pectoris Drugs Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The angina pectoris drugs market size has grown strongly in recent years. It will grow from $11.82 billion in 2023 to $12.47 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to high prevalence of cardiovascular diseases, aging population demographics, lifestyle factors, increase in hypertension rates, diabetes prevalence ..

The angina pectoris drugs market size is expected to see strong growth in the next few years. It will grow to $15.48 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to rising global obesity rates, advancements in precision medicine, focus on preventive cardiology, patient education initiatives, research on novel therapeutic targets .. Major trends in the forecast period include telemedicine for remote monitoring, real-world evidence and outcome studies, patient-centric medication education, strategic alliances for market access, regulatory advances and expedited approvals..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp

Market Segmentation:
The angina pectoris drugs market covered in this report is segmented -

1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs
2) By Indication: Stable Angina, Unstable Angina, Prinzmetal's Angina
3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Major Driver - Surging Prevalence Of Chronic Angina Pectoris Propels Growth In The Angina Pectoris Drug Market
The increasing prevalence of chronic angina pectoris is expected to propel the growth of the angina pectoris drug market going forward. Chronic angina pectoris is chest pain or discomfort caused by reduced blood flow to the heart muscle. Angina pectoris drugs are vital in treating chronic angina. They can provide several benefits to those suffering from this illness, including coronary heart disease, cardiovascular disease, high blood pressure, and being overweight or obese. For instance, in May 2023, according to the Centers for Disease Control and Prevention Highlights, a US-based intergovernmental organization, coronary heart disease killed round 375,476 people in 2021 where, roughly one in every twenty people aged 20 and over (5%). Further, in 2021, almost 2 out of every 10 deaths from coronary artery disease are expected to occur in people under 65. Furthermore, in December 2022, according to the National Library of Medicine, a national center for biological information, Angina affects more than 10 million people in the United States, with more than 500,000 new diagnoses each year. Therefore, the increasing prevalence of chronic angina pectoris is driving the growth of the angina pectoris drug market.

Competitive Landscape:
Major companies operating in the angina pectoris drugs market report are Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Amgen Inc., Gilead Sciences Inc., Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Otsuka Pharmaceutical Co Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, AbbVie Inc., Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Sanofi SA, Sun BioPharma Inc., Atox Bio Inc., CalciMedica Inc., D-Pharm Ltd., Dynavax Technologies Corporation, Fresenius SE & Co KGaA, Olympus Corporation, SCM Lifescience Co. Ltd., Allergan plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Johnson & Johnson,

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Top Trend - Hikma Pharmaceuticals Unveils Labetalol Hydrochloride Injection, Usp, Marking A Milestone In Angina Pectoris Drug Market
Product innovation is a key trend gaining popularity in angina pectoris drugs market. Major companies operating in the angina pectoris drug market are adopting new technologies to sustain their position in the market. For instance, in March 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched Labetalol Hydrochloride Injection, USP, in a prefilled syringe. The Food and Drug Administration of the United States has authorized this product. In hospitals, 10 mg/2 mL PFS is used to treat severe hypertension and lower blood pressure.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Angina Pectoris Drugs Market Characteristics
3. Angina Pectoris Drugs Market Trends And Strategies
4. Angina Pectoris Drugs Market - Macro Economic Scenario
5. Angina Pectoris Drugs Market Size And Growth
…..
27. Angina Pectoris Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Angina Pectoris Drugs Market Analysis 2024 -2033: Forecasted Market Size, Top Segments, And Largest Region | Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Amgen Inc., Gilead Sciences Inc., Bausch Health Companies Inc here

News-ID: 3429195 • Views:

More Releases from The Business research company

Foam Tape Industry to Achieve $14.62 Billion Growth by 2029
Foam Tape Industry to Achieve $14.62 Billion Growth by 2029
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments. How Will the Foam Tape Market Grow by 2025 in Terms of Size and Growth? In recent times, there has been significant growth in the market size for foam tape. It is projected to escalate from $10.02 billion in 2024 to $10.77 billion in 2025, demonstrating a compound annual growth rate (CAGR)
Continuous Positive Airway Pressure (CPAP) Mask Market Expansion Outlook: $3.85 Billion in 2029
Continuous Positive Airway Pressure (CPAP) Mask Market Expansion Outlook: $3.85 …
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments. What Is the Projected CAGR for the Continuous Positive Airway Pressure (CPAP) Mask Market from 2024 to 2025? In recent times, the market size of the continuous positive airway pressure (cpap) mask has seen robust growth. The market is projected to rise from $2.83 billion in 2024 to $3 billion in 2025,
Alkyd Coating Market to Record 7.5% CAGR Growth Through 2029 | Global Analysis Report
Alkyd Coating Market to Record 7.5% CAGR Growth Through 2029 | Global Analysis R …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide. Alkyd Coating Market Outlook: How is the Market Expected to Grow by 2025? The market size of alkyd coatings has experienced significant growth in the past few years. The market is projected to expand from $25.13 billion in 2024 to $26.74 billion in 2025, exhibiting a compound annual growth rate
Water Free Skincare Market Analysis: $22.5 Billion by 2029 With a CAGR of 7%
Water Free Skincare Market Analysis: $22.5 Billion by 2029 With a CAGR of 7%
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports. Water Free Skincare Market Value Projection: How Much Will the Market Size by 2025? The market size of waterless skincare has experienced a robust increase in recent years. The expected growth is from $15.96 billion in 2024 to $17.15 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%.

All 5 Releases


More Releases for Angina

Angina (Angina Pectoris) Pipeline: 10+ Companies Transforming Chest Pain Managem …
The angina therapeutics pipeline is experiencing a renaissance, driven by pharmaceutical companies such as Abbott Laboratories, AstraZeneca, Bayer AG, and Bristol-Myers Squibb. With a focus on improving myocardial efficiency and reducing ischemic burden, emerging therapies-including metabolic modulators, nitric oxide donors, and gene therapies-aim to offer more effective symptom relief and reduce cardiovascular events. Innovations are targeting both stable and microvascular angina forms, addressing the significant unmet needs in chronic angina
Key Influencer in the Angina Pectoris Drugs Market Outlook 2025: Surging Prevale …
What market dynamics are playing a key role in accelerating the growth of the angina pectoris drugs market? The surge in cardiovascular diseases is anticipated to kick-start the expansion of the angina pectoris drug market. The scope of cardiovascular diseases includes diverse disorders affecting the heart and blood vessels, such as stroke, coronary artery disease, hypertension, and heart failure. The rising prevalence of cardiovascular diseases (CVD) is linked to numerous elements,
What's Driving the Angina Market 2025-2034: The Rising Prevalence of Coronary Ar …
What Are the Projections for the Size and Growth Rate of the Angina Market? The scale of the angina market has seen robust growth in the previous years. The expansion is expected to continue, increasing from a value of $10.71 billion in 2024 to $11.4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.4%. The surge in the past period can be credited to factors such as a
Angina Pectoris - Drug Pipeline Landscape, 2022
Global Angina Pectoris Market report from Global Insight Services is the single authoritative source of intelligence on angina pectoris market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,
Angina Pectoris - Drug Pipeline Landscape, 2022
Angina also known as angina pectoris, is a type of chest pain or discomfort that occurs when a part of the heart doesn't get enough blood and oxygen, which is due to the spasm or obstruction of the arteries that supply the blood to the heart muscles. Angina is mainly of four types: stable angina, unstable angina, microvascular angina, and vasospastic or variant angina. Angina is caused due to the built
Angina Pectoris Drugs Market Set for Rapid Growth
Global Angina Pectoris Drugs Market: Overview The demand within the global market for angina pectoris drugs has been rising on account of the focus given on treating medical conditions suffered by the geriatric population. The presence of a seamless industry for healthcare diagnostic and treatment has played a major role in market growth. Angina pectoris is a type of chest pain that is triggered due to reduced blood flow to